NASDAQ:CYTT Cyteir Therapeutics (CYTT) Stock Price, News & Analysis → Collect 10%+ Dividends from AI's Explosive Growth? (From The Oxford Club) (Ad) Free CYTT Stock Alerts $3.01 -0.01 (-0.33%) (As of 03/18/2024) Add Compare Share Share Today's Range$2.92▼$3.1950-Day Range$3.01▼$3.0152-Week Range$1.65▼$3.19Volume551,300 shsAverage VolumeN/AMarket Capitalization$108.36 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsSEC FilingsTrendsStock AnalysisChartEarningsFinancialsSEC FilingsTrends Get Cyteir Therapeutics alerts: Email Address Ad The Oxford ClubCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having to buy a single stock?Click here now to claim your FREE copy of Marc's AI playbook. About Cyteir TherapeuticsCyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts.Read More CYTT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYTT Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com Receive CYTT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cyteir Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today6/15/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CYTT CUSIPN/A CIK1662244 Webcyteir.com Phone857-285-4140FaxN/AEmployees46Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-46,060,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-24.88% Return on Assets-23.83% Debt Debt-to-Equity RatioN/A Current Ratio21.89 Quick Ratio21.89 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.13 per share Price / Book0.73Miscellaneous Outstanding Shares36,000,000Free Float30,814,000Market Cap$108.36 million OptionableN/A Beta0.09 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Joseph S. Zakrzewski (Age 62)Independent Investor & Independent Chairman of the Board Comp: $81.5kDr. Markus F. Renschler M.D. (Age 63)President, CEO & Director Comp: $718.62kDr. Kevin Mills Ph.D.Co-FounderMr. David G. Gaiero (Age 46)CFO & Treasurer Key CompetitorsTheravance BiopharmaNASDAQ:TBPHPrecigenNASDAQ:PGENContineum TherapeuticsNASDAQ:CTNMKorro BioNASDAQ:KRROErascaNASDAQ:ERASView All Competitors CYTT Stock Analysis - Frequently Asked Questions How have CYTT shares performed in 2024? Cyteir Therapeutics' stock was trading at $3.01 on January 1st, 2024. Since then, CYTT shares have increased by 0.0% and is now trading at $3.01. View the best growth stocks for 2024 here. How do I buy shares of Cyteir Therapeutics? Shares of CYTT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CYTT) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredKiss of death from Joe BidenI did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but Biden does ...Porter & Company | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyteir Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyteir Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.